GLP1 NAION warning: FDA orders class-wide labels for potential rare eye risk

Пункты, о которых сообщило больше одного издания

1. FDA requirement for NAION warnings on GLP-1 labels3 издания
2. NAION effects on vision2 издания
3. Drugs covered by the FDA labeling requirement2 издания
4. Evidence included in the FDA evaluation2 издания